SG11201408095XA - Fibroblast growth factor 21 proteins - Google Patents
Fibroblast growth factor 21 proteinsInfo
- Publication number
- SG11201408095XA SG11201408095XA SG11201408095XA SG11201408095XA SG11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA SG 11201408095X A SG11201408095X A SG 11201408095XA
- Authority
- SG
- Singapore
- Prior art keywords
- indiana
- indianapolis
- company
- international
- eli lilly
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 4
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 102000056713 human FGF21 Human genes 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
- Y10S530/814—Cellulose or derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261658104P | 2012-06-11 | 2012-06-11 | |
| US201361777386P | 2013-03-12 | 2013-03-12 | |
| PCT/US2013/044190 WO2013188181A1 (en) | 2012-06-11 | 2013-06-05 | Fibroblast growth factor 21 proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408095XA true SG11201408095XA (en) | 2015-01-29 |
Family
ID=48670814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408095XA SG11201408095XA (en) | 2012-06-11 | 2013-06-05 | Fibroblast growth factor 21 proteins |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8741841B2 (forum.php) |
| EP (1) | EP2858662B1 (forum.php) |
| JP (1) | JP6182600B2 (forum.php) |
| KR (1) | KR20150006060A (forum.php) |
| CN (1) | CN104394882B (forum.php) |
| AR (1) | AR091216A1 (forum.php) |
| AU (1) | AU2013274638A1 (forum.php) |
| BR (1) | BR112014029966A2 (forum.php) |
| CA (1) | CA2871145A1 (forum.php) |
| CL (1) | CL2014003078A1 (forum.php) |
| CO (1) | CO7151525A2 (forum.php) |
| EA (1) | EA201492053A1 (forum.php) |
| EC (1) | ECSP14030742A (forum.php) |
| ES (1) | ES2644787T3 (forum.php) |
| HK (1) | HK1203357A1 (forum.php) |
| IL (1) | IL235832A0 (forum.php) |
| IN (1) | IN2014MN02132A (forum.php) |
| MX (1) | MX2014015257A (forum.php) |
| PE (1) | PE20150201A1 (forum.php) |
| PH (1) | PH12014502766A1 (forum.php) |
| SG (1) | SG11201408095XA (forum.php) |
| TN (1) | TN2014000439A1 (forum.php) |
| TW (1) | TWI513705B (forum.php) |
| WO (1) | WO2013188181A1 (forum.php) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2068909T3 (da) | 2007-03-30 | 2012-08-06 | Ambrx Inc | Modificerede FGF-21-polypeptider og anvendelse heraf |
| HRP20191713T1 (hr) | 2011-07-01 | 2019-12-27 | Ngm Biopharmaceuticals, Inc. | Pripravci, uporabe i metode za liječenje metaboličkih poremećaja i bolesti |
| AU2013274639A1 (en) * | 2012-06-11 | 2014-11-06 | Eli Lilly And Company | Fibroblast growth factor 21 variants |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| AU2013352363B2 (en) | 2012-11-28 | 2018-04-12 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| PL2938740T3 (pl) | 2012-12-27 | 2022-07-11 | Ngm Biopharmaceuticals, Inc. | Chimeryczne peptydy fgf19 do zastosowania w leczeniu zaburzeń gospodarki kwasami żółciowymi |
| KR102178945B1 (ko) | 2013-10-28 | 2020-11-13 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 암 모델 및 관련 방법 |
| SG10201806108TA (en) | 2014-01-24 | 2018-08-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| BR112016017402A2 (pt) | 2014-02-21 | 2017-10-17 | Medimmune Ltd | fusões anti-pcsk9~glp-1 e métodos para uso |
| JP6712230B2 (ja) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
| CA2943355C (en) | 2014-03-25 | 2023-09-05 | Regeneron Pharmaceuticals, Inc. | Fgf21 receptor agonists and uses thereof |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| EP3155005A4 (en) | 2014-06-16 | 2018-07-11 | NGM Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10293026B2 (en) | 2014-09-08 | 2019-05-21 | Osaka University | Agent for preventing or treating demyelinating disease |
| EP3209681B1 (en) | 2014-10-23 | 2025-04-02 | NGM Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| PL3412302T3 (pl) | 2014-10-24 | 2021-11-02 | Bristol-Myers Squibb Company | Zmodyfikowane polipeptydy fgf-21 i ich zastosowania |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| KR20160088656A (ko) * | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| WO2016187558A2 (en) | 2015-05-20 | 2016-11-24 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method to improve neurologic outcomes in temperature managed patients |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| CN105348380B (zh) * | 2015-12-28 | 2019-03-01 | 江苏康缘瑞翱生物医药科技有限公司 | 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途 |
| WO2018032638A1 (zh) | 2016-08-19 | 2018-02-22 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| CN107759697B (zh) | 2016-08-19 | 2023-03-24 | 安源医药科技（上海）有限公司 | 制备融合蛋白的方法 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| NZ752661A (en) | 2016-11-10 | 2025-10-31 | Yuhan Corp | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |
| ES3014984T3 (en) | 2017-03-14 | 2025-04-28 | Sunshine Lake Pharma Co Ltd | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| EP3612637A4 (en) | 2017-04-21 | 2021-01-27 | Yuhan Corporation | DOUBLE-FUNCTION PROTEIN PRODUCTION PROCESS AND ITS DERIVATIVES |
| CN107385020A (zh) * | 2017-06-23 | 2017-11-24 | 西安医学院 | 瘦素在人重组fgf21蛋白活性检测中的应用 |
| AU2018329850A1 (en) | 2017-09-08 | 2020-04-23 | Bristol-Myers Squibb Company | Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH) |
| JP7475276B2 (ja) | 2018-02-08 | 2024-04-26 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | Ｆｇｆ２１バリアント、融合タンパク質及びそれらの適用 |
| BR112020026512A2 (pt) | 2018-07-03 | 2021-04-06 | Bristol-Myers Squibb Company | Formulações de fgf-21 |
| CN111195234B (zh) * | 2018-11-16 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组FGF21-Fc融合蛋白冻干粉制剂 |
| CN111662373B (zh) * | 2019-03-05 | 2024-05-14 | 广东东阳光药业股份有限公司 | 一种多肽分子及其应用 |
| NZ782268A (en) * | 2019-04-23 | 2025-07-25 | Lg Chemical Ltd | Fusion polypeptide comprising fc region of immunoglobulin and gdf15 |
| IL294534A (en) | 2020-01-08 | 2022-09-01 | Bristol Myers Squibb Co | Fgf-21 conjugate formulations |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| JP2023538533A (ja) | 2020-08-07 | 2023-09-08 | ブリストル－マイヤーズ スクイブ カンパニー | 線維症の処置のための、ｃｃｒ２／５拮抗剤と組み合わせたｆｇｆ２１ |
| KR20220021207A (ko) | 2020-08-13 | 2022-02-22 | 주식회사 나이벡 | 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물 |
| KR102495299B1 (ko) * | 2020-11-03 | 2023-02-06 | 토드제약 주식회사 | Fgf21의 열탄력성을 이용한 fgf21 생산 방법 |
| WO2022115597A1 (en) | 2020-11-25 | 2022-06-02 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| AU2002322394A1 (en) | 2001-07-30 | 2003-02-17 | Eli Lilly And Company | Method for treating diabetes and obesity |
| CA2549249A1 (en) | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| EP1751184B1 (en) * | 2004-05-13 | 2009-09-30 | Eli Lilly And Company | Fgf-21 fusion proteins |
| DK2068909T3 (da) * | 2007-03-30 | 2012-08-06 | Ambrx Inc | Modificerede FGF-21-polypeptider og anvendelse heraf |
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| CH699521A2 (de) | 2008-09-09 | 2010-03-15 | Rotorcraft Ag | Streckwerk für eine Strickmaschine. |
| JP5878757B2 (ja) | 2008-10-10 | 2016-03-08 | アムジエン・インコーポレーテツド | Ｆｇｆ２１変異体およびその使用 |
| WO2010065439A1 (en) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| JP5599822B2 (ja) | 2009-01-23 | 2014-10-01 | ノヴォ ノルディスク アー／エス | アルブミンバインダーａ−ｂ−ｃ−ｄ−ｅ−を有するｆｇｆ２１誘導体及びそれらの使用 |
| RS65153B1 (sr) | 2009-05-05 | 2024-02-29 | Amgen Inc | Fgf21 mutanti i njihove upotrebe |
| CA2760674A1 (en) * | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| WO2011154349A2 (en) * | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| AR087973A1 (es) * | 2011-10-04 | 2014-04-30 | Lilly Co Eli | Variantes del factor 21 del crecimiento de fibroblastos |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
-
2013
- 2013-05-27 TW TW102118698A patent/TWI513705B/zh not_active IP Right Cessation
- 2013-05-30 AR ARP130101904 patent/AR091216A1/es unknown
- 2013-06-05 ES ES13730733.6T patent/ES2644787T3/es active Active
- 2013-06-05 HK HK15103818.7A patent/HK1203357A1/xx unknown
- 2013-06-05 US US13/910,149 patent/US8741841B2/en active Active
- 2013-06-05 EA EA201492053A patent/EA201492053A1/ru unknown
- 2013-06-05 EP EP13730733.6A patent/EP2858662B1/en active Active
- 2013-06-05 JP JP2015517297A patent/JP6182600B2/ja active Active
- 2013-06-05 MX MX2014015257A patent/MX2014015257A/es unknown
- 2013-06-05 CN CN201380030788.4A patent/CN104394882B/zh not_active Expired - Fee Related
- 2013-06-05 WO PCT/US2013/044190 patent/WO2013188181A1/en not_active Ceased
- 2013-06-05 BR BR112014029966A patent/BR112014029966A2/pt not_active IP Right Cessation
- 2013-06-05 IN IN2132MUN2014 patent/IN2014MN02132A/en unknown
- 2013-06-05 AU AU2013274638A patent/AU2013274638A1/en not_active Abandoned
- 2013-06-05 KR KR20147034366A patent/KR20150006060A/ko not_active Abandoned
- 2013-06-05 CA CA2871145A patent/CA2871145A1/en not_active Abandoned
- 2013-06-05 PE PE2014002236A patent/PE20150201A1/es not_active Application Discontinuation
- 2013-06-05 SG SG11201408095XA patent/SG11201408095XA/en unknown
-
2014
- 2014-04-23 US US14/259,210 patent/US8927492B2/en active Active
- 2014-10-20 TN TN2014000439A patent/TN2014000439A1/fr unknown
- 2014-11-13 CL CL2014003078A patent/CL2014003078A1/es unknown
- 2014-11-20 IL IL235832A patent/IL235832A0/en unknown
- 2014-11-27 CO CO14261559A patent/CO7151525A2/es unknown
- 2014-12-10 PH PH12014502766A patent/PH12014502766A1/en unknown
- 2014-12-11 EC ECIEPI201430742A patent/ECSP14030742A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI513705B (zh) | 2015-12-21 |
| ECSP14030742A (es) | 2015-09-30 |
| US8741841B2 (en) | 2014-06-03 |
| ES2644787T3 (es) | 2017-11-30 |
| EP2858662A1 (en) | 2015-04-15 |
| KR20150006060A (ko) | 2015-01-15 |
| CA2871145A1 (en) | 2013-12-19 |
| US8927492B2 (en) | 2015-01-06 |
| US20130330336A1 (en) | 2013-12-12 |
| AR091216A1 (es) | 2015-01-21 |
| CN104394882A (zh) | 2015-03-04 |
| TW201408693A (zh) | 2014-03-01 |
| CO7151525A2 (es) | 2014-12-29 |
| JP6182600B2 (ja) | 2017-08-16 |
| BR112014029966A2 (pt) | 2017-09-12 |
| CL2014003078A1 (es) | 2015-02-27 |
| CN104394882B (zh) | 2016-06-22 |
| PH12014502766A1 (en) | 2015-02-09 |
| IN2014MN02132A (forum.php) | 2015-09-11 |
| EA201492053A1 (ru) | 2015-02-27 |
| US20140228282A1 (en) | 2014-08-14 |
| MX2014015257A (es) | 2015-03-05 |
| AU2013274638A1 (en) | 2014-11-06 |
| PE20150201A1 (es) | 2015-02-19 |
| WO2013188181A1 (en) | 2013-12-19 |
| HK1203357A1 (en) | 2015-10-30 |
| IL235832A0 (en) | 2015-01-29 |
| JP2015527974A (ja) | 2015-09-24 |
| TN2014000439A1 (en) | 2016-03-30 |
| EP2858662B1 (en) | 2017-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201408261UA (en) | Syringe | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201900844UA (en) | Amino pyrimidine ssao inhibitors | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201907032RA (en) | Amino pyrimidine compounds useful as ssao inhibitors | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201407801VA (en) | Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations |